Cyclic Vomiting Syndrome (CVS)
Rome IV diagnosis, CVS vs. CHS vs. functional vomiting, biopsychosocial management, TCA prophylaxis, and sumatriptan abortive therapy. Based on Frazier, Li & Venkatesan. AJG 2023.
Rome IV criteria & epidemiology
Cyclic Vomiting Syndrome — What Is It?
CVS is a chronic, episodic disorder characterized by recurrent, stereotypical episodes of severe nausea and vomiting separated by symptom-free intervals. It is a brain-gut disorder — not a gastric disease — and is underdiagnosed in adults.
Rome IV Diagnostic Criteria
All must be fulfilled over the last 6 months:
Supportive Features
Personal or family history of migraine; stereotypy (each episode similar to prior ones); relief with hot showers/baths; nocturnal onset; identifiable triggers (stress, menses, specific foods).
Epidemiology
Four Phases of CVS
Common Triggers
Psychological
• Emotional stress
• Excitement/anticipation
• Panic attacks
Physical
• Sleep deprivation
• Physical exhaustion
• Menses
• Infections
Dietary
• Cheese, chocolate
• Alcohol
• MSG
• Fasting
Diagnostic Workup — When & What (Frazier 2023)
CVS is a clinical diagnosis based on Rome IV criteria. However, targeted testing is needed to exclude organic causes, especially on first presentation.
All patients (first episode)
• CBC, CMP, lipase, TSH
• Urine HCG (women of childbearing age)
• Upper endoscopy if alarm features present
• Consider brain MRI if headache or neurologic sx
Consider in select patients
• Gastric emptying study (exclude gastroparesis)
• Small bowel follow-through / CT enterography
• Mitochondrial DNA testing (maternal inheritance pattern)
• Urine organic acids (rule out metabolic disorder)
Key Point from Frazier 2023
The diagnosis of CVS should not be one of exclusion by extensive testing — a positive pattern recognition approach using Rome IV criteria and stereotypy is preferred. Overinvestigation contributes to the average 6-year diagnostic delay.
Frazier R, Li BUK, Venkatesan T. Am J Gastroenterol 2023;118(7):1157–67; Venkatesan T et al. Neurogastroenterol Motil 2019; Rome IV 2016.